formalininactiv
japanes
enceph
viru
jev
vaccin
wide
avail
effect
formalin
inactiv
antigen
structur
jev
profil
antibodi
elicit
vaccin
well
understood
use
panel
monoclon
antibodi
mab
map
antigen
structur
live
jev
viru
untreat
control
viru
ucv
formalininactiv
commerci
vaccin
ficv
formalininactiv
viru
fiv
bind
activ
mab
nakayamaderiv
ficv
sever
strain
fiv
significantli
lower
compar
live
viru
ucv
mab
weakli
neutral
jev
serocomplex
antibodi
found
inhibit
jev
infect
postattach
step
epitop
map
amino
acid
within
domain
iii
ediii
envelop
e
glycoprotein
explor
effect
formalin
inactiv
immunogen
jev
found
nakayamaderiv
ficv
fiv
ucv
exhibit
similar
immunogen
mous
model
induc
antijev
antiedii
epitopespecif
antibodi
howev
ediii
epitopespecif
igg
antibodi
neutral
antibodi
titer
significantli
lower
ficvimmun
fivimmun
mous
serum
ucvimmun
formalin
inactiv
seem
alter
antigen
structur
e
protein
may
reduc
potenc
commerci
avail
jev
vaccin
viru
inactiv
h
uv
shortdur
higher
temperatur
formalin
treatment
abl
maintain
antigen
structur
jev
e
protein
thu
altern
inactiv
method
h
abl
maintain
integr
e
protein
may
essenti
improv
potenc
inactiv
jev
vaccin
demonstr
formalin
inactiv
japanes
enceph
viru
jev
alter
antigen
structur
jev
envelop
glycoprotein
e
particular
epitop
domain
iii
reduc
abil
inactiv
vaccin
elicit
protect
neutral
antibodi
other
previou
studi
highlight
import
improv
immunogen
genotyp
iii
giii
deriv
jev
vaccin
order
provid
crossprotect
genotyp
gi
virus
emerg
replac
giii
virus
mani
jevendem
region
encourag
wide
use
liveattenu
chimer
vaccin
yellowfev
vaccin
respect
develop
gi
virusderiv
inactiv
premembraneecontain
noninfecti
viruslik
particl
vlp
vaccin
two
possibl
way
address
potenti
problem
exploratori
studi
highlight
altern
inactiv
method
h
treatment
may
improv
antigen
stabil
immunogen
jev
japanes
enceph
viru
jev
import
etiolog
agent
viral
enceph
asian
countri
caus
regular
outbreak
eastern
southeastern
asia
india
recent
australia
annual
japanes
enceph
je
confirm
case
report
jev
endem
area
symptomat
cn
infect
fatal
symptomat
survivor
longterm
neurolog
sequela
asymptomat
jev
infect
thousandfold
higher
confirm
case
jev
transmit
virusinfect
culex
mosquito
inappar
infect
viremicamplifi
host
pig
aquat
bird
symptomat
accident
host
hors
human
migratori
bird
implic
sourc
viru
introduc
new
geograph
region
associ
je
epidem
replac
genotyp
iii
giii
genotyp
gi
jev
southeast
asia
east
asia
genom
jev
consist
positivesens
singlestrand
rna
translat
process
viral
host
proteas
three
structur
proteinscapsid
precursor
membranemembran
protein
prmm
envelop
glycoprotein
e
seven
nonstructur
protein
ns
matur
virion
consist
e
protein
form
homodim
process
protein
immatur
virion
form
e
prm
heterotrim
e
protein
critic
protein
elicit
protect
immun
host
viral
infect
offer
critic
protect
mice
induc
protect
antibodi
recov
human
ectodomain
e
protein
separ
three
structur
domain
e
domain
edi
iii
ediii
fusion
peptid
edii
elicit
group
crossreact
nonor
lowneutr
antibodi
ediii
receptorbind
domain
elicit
potent
typespecif
neutral
antibodi
edi
center
domain
connect
edii
ediii
elicit
complex
crossreact
highor
nonneutr
antibodi
viral
infect
vaccin
remain
effect
strategi
control
je
epidem
liveattenu
formalininactiv
jev
vaccin
avail
human
use
liveattenu
vaccin
avail
domest
anim
swine
hors
first
gener
inactiv
jev
vaccin
develop
biken
japan
mous
brainderiv
formalininactiv
giii
nakayama
strain
manufactur
vaccin
ceas
sinc
undesir
advers
effect
second
gener
tissu
culturederiv
formalinformalin
inactiv
alter
immunogen
jev
plo
neglect
tropic
diseas
introduct
inactiv
vaccin
formul
aluminumhydroxideadjuv
ixiaro
vaccin
licens
use
adult
children
older
month
addit
liveattenu
jev
vaccin
develop
china
use
asian
countri
china
india
nepal
vaccin
effect
estim
two
dose
inactiv
nakayama
vaccin
one
dose
liveattenu
vaccin
unlik
liveattenu
vaccin
formalininactiv
jev
vaccin
requir
boost
immun
retain
protect
neutral
antibodi
signific
number
jev
endem
countri
still
depend
local
produc
mous
brainderiv
formalininactiv
giii
jev
vaccin
control
je
epidem
formalin
chemic
commonli
use
inactiv
manufactur
viral
vaccin
hepat
viru
polio
influenza
viru
rabi
viru
simian
immunodefici
viru
formalin
react
amino
acid
target
protein
form
revers
schiffbas
adduct
nonrevers
methylen
bridg
also
use
isotop
agent
label
protein
introduc
isotop
specif
amino
acid
cell
tissu
fixat
agent
formalin
function
chemic
use
inactiv
viru
chemic
reaction
may
modifi
antigen
structur
virion
shown
formalin
inactiv
alter
antigen
properti
reduc
immunogen
vaccin
hepat
b
viru
polio
viru
bovin
herp
viru
influenza
viru
mous
model
formalininactiv
jev
vaccin
remain
wide
distribut
vaccin
use
control
je
epidem
howev
potenti
effect
formalin
antigen
structur
jev
antibodi
profil
elicit
vaccin
remain
unclear
use
low
concentr
formalin
short
inactiv
time
yield
antigen
capabl
induc
high
neutral
titer
mice
associ
inactiv
procedur
alter
antigen
structur
e
antibodi
profil
elicit
vaccin
remain
undetermin
studi
use
panel
especif
murin
monoclon
antibodi
mab
analyz
effect
epitop
modif
jev
e
protein
formalininactiv
commerci
vaccin
ficv
laboratori
grown
formalininactiv
giii
gi
virus
fiv
show
formalininactiv
inde
alter
bind
pattern
jevderiv
serocomplex
crossreact
neutral
antibodi
interestingli
antibodi
recogn
formalinmodifi
epitop
significantli
lower
titer
weaker
neutral
activ
serum
mice
vaccin
ficv
fivnakayama
untreat
control
nakayama
viru
ucvnakayama
h
inactiv
jev
superior
approach
retain
antigen
reactiv
viru
test
mab
includ
compar
convent
inactiv
method
formalin
uv
anim
experi
approv
institut
anim
care
use
committe
iacuc
nation
chung
hsing
univers
taiwan
approv
perform
accord
protocol
adher
principl
guid
care
use
laboratori
anim
nrc
meet
requir
associ
assess
accredit
laboratori
anim
care
aaalac
serum
sampl
use
studi
collect
anonym
children
receiv
jev
vaccin
without
jev
infect
part
alreadyexist
collect
hous
tung
taichung
metroharbor
hospit
taichung
clinic
protocol
review
approv
institut
review
board
hospit
serum
sampl
collect
serum
recov
blood
clot
centrifug
store
use
vero
cell
kindli
provid
dr
chang
gj
us
cdc
fort
collin
co
grown
dulbeco
modifi
eagl
minim
essenti
medium
dmem
gibco
contain
heatinactiv
fetal
bovin
serum
fb
gibco
respect
bhk
cell
kindli
provid
dr
chen
wj
chang
gung
univers
taiwan
grown
minimum
essenti
medium
mem
gibco
heatinactiv
fb
jev
vaccin
strain
use
giii
strain
nakayama
natur
attenu
giii
isol
gi
circul
strain
ficv
use
studi
mous
brainderiv
formalininactiv
nakayama
viru
vaccin
manufactur
adimmun
corp
taiwan
monoclon
antibodi
mab
use
antigen
character
flaviviru
group
crossreact
mab
jev
serocomplex
crossreact
mab
jevspecif
mab
vero
cell
infect
strain
jev
name
nakayama
multipl
infect
moi
grown
serumfre
medium
hyclon
logan
ut
day
supernat
clarifi
centrifug
rpm
min
virion
particl
supernat
pellet
second
centrifug
rpm
hr
viral
pellet
second
centrifug
resuspend
phosphat
buffer
salin
pb
concentr
virus
use
deriv
fiv
amount
formaldehyd
sigmaaldrich
st
loui
mo
dilut
pb
adjust
ph
n
naoh
sigmaaldrich
st
loui
mo
mixtur
ad
concentr
jev
virus
give
final
formalin
concentr
formalintr
viru
fiv
untreat
viru
untreat
control
viru
ucv
incub
day
manufactur
procedur
ficv
provid
adimmun
corpor
taiwan
day
fiv
ucv
sampl
incub
collect
everi
week
store
analysi
nakayama
viru
specimen
inactiv
shortwavelength
uv
light
distanc
cm
ice
min
final
concentr
h
fisher
scientif
ph
hr
store
residu
infecti
viral
titer
fiv
ucv
uvor
h
treat
virus
assess
microplaqu
assay
antigencaptur
ag
enzymelink
immunosorb
assay
elisa
antigencaptur
elisa
agelisa
describ
previous
use
estim
e
protein
concentr
sampl
antijev
mous
hyperimmun
acit
fluid
mhiaf
immun
purifi
live
jev
determin
bind
activ
mab
briefli
plate
sigmaaldrich
st
loui
mo
coat
rabbit
antijev
polyclon
gener
rabbit
immun
pvaxjei
vlpexpress
plasmid
obtain
dr
chang
gj
us
cdc
fort
collin
co
hr
block
startblock
block
buffer
pierc
rockford
ill
antigen
ad
ng
per
well
incub
overnight
antigen
incub
mab
mhiaf
dilut
skim
milk
hr
peroxidaseconjug
goat
antimous
igg
hl
jackson
immunoresearch
west
grove
pa
hr
final
substrat
tmb
neogen
corp
lexington
ky
ad
per
well
color
reaction
reaction
stop
h
ad
per
well
od
valu
record
antigen
concentr
ucv
fiv
estim
od
mhiaf
mab
bind
activ
ucv
fiv
determin
percentag
reactiv
estim
od
ucv
fiv
time
rel
respect
bind
activ
adjust
fold
differ
antigen
concentr
estim
mhiaf
ucv
fiv
time
rel
respect
shown
two
duplic
two
independ
assay
jev
jev
viruslik
particl
vlp
mix
sd
nonreduc
sampl
buffer
mm
tri
ph
glycerol
sd
bromophenol
blue
load
onto
sd
gel
separ
protein
transfer
nitrocellulos
membran
block
skim
milk
protein
membran
detect
use
mous
antijev
polyclon
antibodi
mab
mhiaf
visual
incub
peroxidaseconjug
goat
antimous
igg
hl
jackson
immunoresearch
west
grove
pa
band
develop
use
lumigold
ecl
western
blot
detect
kit
signagen
laboratori
gaithersburg
md
intens
band
calcul
use
imagej
version
nih
bethesda
md
bind
activ
antiedii
antiediii
antibodi
vlp
elimin
introduc
mutat
vlp
respect
jev
vlp
produc
pvaxjei
plasmid
deriv
pcbje
plasmid
encod
prm
e
protein
region
strain
genom
plasmid
also
use
templat
introduc
mutat
e
protein
use
sitedirect
mutagenesi
kit
stratagen
la
jolla
ca
describ
pvaxjei
amino
acid
mutant
introduc
mutagenesi
primer
tabl
accord
manufactur
protocol
mutat
confirm
sequenc
jev
vlpexpress
plasmid
electropor
cell
use
cuvett
biorad
gene
pulser
ii
biorad
laboratori
hercul
ca
v
electropor
cell
recov
overnight
incub
enhanc
vlp
secret
secret
vlp
analyz
agelisa
use
evalu
presenc
epitopespecif
antibodi
measur
neutral
activ
mab
serum
sampl
briefli
vero
cell
ad
plate
hr
co
mab
preattach
assay
serum
sampl
inactiv
min
dilut
twofold
seri
mix
pfu
jev
nakayama
strain
hr
shaken
everi
min
monolay
vero
cell
infect
virusantibodi
mixtur
hr
co
contrast
postattach
assay
viru
bound
monolay
vero
cell
hour
incub
twofold
seri
dilut
inactiv
mab
hour
shift
incub
hour
incub
methyl
cellulos
dmem
contain
fb
ad
plate
incub
hr
co
plate
wash
pb
fix
aceton
airdri
hood
fix
cell
stain
antijev
mhiaf
min
wash
peroxidaseconjug
goat
antimous
igg
jackson
immunoresearch
west
grove
pa
ad
min
virusinfect
foci
identifi
use
vectorvip
peroxidas
substrat
kit
vector
laboratori
burlingam
ca
foci
count
manual
microscopi
use
calcul
sigmoid
doserespons
focu
reduct
microneutr
test
titer
use
graphpad
prism
mous
immun
epitopespecif
antibodi
respons
group
old
balbc
mice
n
mice
per
group
vaccin
three
dose
freund
incomplet
adjuv
ucvnakayama
fivnakayama
ficv
first
booster
vaccin
given
primari
immun
follow
final
booster
week
first
booster
vaccin
serum
sampl
collect
week
final
booster
vaccin
igg
antibodycaptur
elisa
gacelisa
describ
previous
use
determin
titer
epitopespecif
antibodi
immun
mous
serum
briefli
goat
antimous
igg
hl
kpl
gaithersburg
md
coat
plate
hr
plate
block
startblock
block
buffer
pierc
rockford
ill
serum
sampl
serial
dilut
wash
buffer
ad
plate
min
wash
ng
jev
antigen
wildtyp
wt
mutant
jev
vlp
ad
mixtur
incub
overnight
iggcaptur
antigen
detect
use
rabbit
antijev
polyclon
antibodi
peroxidaseconjug
goat
antirabbit
igg
hl
jackson
immunoresearch
west
grove
pa
detect
antigenbound
rabbit
antijev
polyclon
antibodi
step
describ
agelisa
total
antiimmunogen
igg
antibodi
determin
endpoint
titer
epitopespecif
antibodi
respons
determin
decreas
reactiv
titer
mutant
vlp
compar
wt
vlp
calcul
endpoint
titer
wtmutant
vlp
epitopespecif
neutral
antibodi
activ
determin
follow
pvax
jei
wt
ediii
mutant
plasmid
electropor
cell
cultur
hr
cell
resuspend
pb
dilut
mous
serum
sampl
mix
transform
cell
shaker
hr
transform
cell
remov
centrifug
rpm
min
supernat
contain
unbound
antibodi
serial
dilut
mix
plaqueform
unit
pfu
jev
nakayama
strain
hr
neutral
activ
determin
assay
describ
previous
neutral
activ
calcul
pvaxjei
wt
ediii
mutant
plasmidtransform
cell
seed
well
chamber
slide
millipor
billerica
cultur
overnight
well
fix
paraformaldehyd
sigma
st
loui
mo
usa
pb
room
temperatur
min
wash
pb
fix
cell
made
permeabl
treatment
triton
min
wash
pb
well
block
bovin
serum
albumin
sigma
st
loui
mo
usa
pb
hr
well
stain
antijev
mhiaf
react
fitcconjug
goat
antimous
igg
kpl
gaithersburg
md
evan
blue
imag
view
olympu
microscop
data
present
two
repeat
experi
twotail
student
test
use
analys
statist
signific
set
p
antibodi
elicit
jev
infect
immun
conformationdepend
part
recogn
viral
e
protein
abl
help
prevent
viru
infect
formalin
inactiv
sever
human
vaccin
shown
result
antigen
alter
viral
particl
measur
bind
activ
specif
mab
effect
formalin
inactiv
commerci
avail
jev
vaccin
evalu
previous
establish
agelisa
protocol
success
use
determin
antigen
structur
jev
use
panel
anti
protein
mab
first
evalu
antigen
differ
live
nakayama
viru
ficv
agelisa
use
panel
eleven
antiflaviviru
eprotein
mab
antigen
concentr
estim
agelisa
use
jevspecif
mhiaf
live
viru
ficv
use
throughout
experi
live
nakayama
viru
ficv
show
similar
bind
pattern
ten
eleven
test
mab
except
mab
fig
bind
activ
mab
significantli
lower
ficv
live
nakayama
viru
p
endpoint
titer
live
nakayama
viru
ficv
respect
mab
bind
pattern
suggest
antigen
structur
ficv
differ
live
nakayama
viru
decreas
bind
activ
mab
ficv
might
due
procedur
variat
vaccin
manufactur
includ
differ
formalin
inactiv
differ
viru
purif
process
chang
substrain
use
differ
passag
histori
nakayama
viru
use
vaccin
product
viru
strain
live
nakayama
viru
use
experi
rule
potenti
influenc
substrain
differ
e
structur
focu
effect
formalin
treatment
antigen
modif
nakayama
viru
subject
laboratorygrown
concentr
nakayama
viru
either
formalin
inactiv
fivnakayama
without
formalin
day
untreat
control
virusnakayama
viru
ucvnakayama
antigen
reactiv
fivnakayama
ucvnakayama
determin
agcaptur
elisa
antijev
mhiaf
remain
constant
fig
infect
fivnakayama
decreas
drastic
detect
limit
day
treatment
condit
howev
infect
ucvnakayama
decreas
gradual
time
becam
undetect
day
fig
ten
eleven
mab
except
show
similar
bind
activ
fivnakayama
ucvnakayama
prepar
collect
time
point
agelisa
fig
bind
activ
jev
serocomplex
crossreact
mab
fivnakayama
significantli
decreas
collect
point
sampl
bind
activ
sampl
decreas
bind
fivnakayama
timedepend
bind
activ
remain
fig
panel
e
unlik
bind
fivnakayama
declin
earli
time
point
compar
ucvnakayama
observ
later
time
point
result
consist
observ
exhibit
decreas
bind
activ
ficv
agelisa
fig
therefor
believ
decreas
bind
activ
mab
ficv
result
formalin
inactiv
relat
potenti
antigen
differ
relat
substrain
viru
associ
passag
histori
viru
rule
formalininduc
antigen
modif
occur
strainspecif
amino
acid
prepar
three
differ
strain
jev
giii
vaccinestrain
viru
natur
attenu
giii
viru
gi
viru
appli
formalin
inactiv
procedur
three
virus
follow
measur
mab
bind
agelisa
use
subset
eight
mab
pattern
mab
bind
activ
obtain
virus
similar
obtain
nakayama
viru
without
formalin
treatment
fig
fig
bind
activ
mab
significantli
decreas
respect
fig
confirm
decreas
bind
activ
mab
e
protein
due
formalin
inactiv
viral
prepar
without
formalin
treatment
analyz
nonreduc
sd
page
follow
western
blot
use
mab
similar
agelisa
bind
activ
fivjev
ucvjev
antigen
includ
comparison
fig
fig
intens
e
protein
band
detect
variou
fivjev
ucvjev
includ
nakayama
similar
howev
intens
detect
lower
fivjev
ucvjev
fig
way
comparison
formalintr
nakayama
virus
found
reduc
bind
intens
ucvjev
respect
fig
therefor
formalin
inactiv
affect
antigen
structur
jev
e
protein
would
seem
viral
strainspecif
like
occur
virion
level
perhap
affect
e
monom
contain
disulfid
bond
local
formalinmodifi
epitop
e
protein
map
epitop
recogn
mab
antigen
structur
noninfecti
jev
vlp
similar
virion
particl
mab
jev
serocomplex
crossreact
antibodi
previous
found
amino
acid
residu
present
edii
amino
acid
residu
present
ediii
import
bind
jev
serocomplex
crossreact
mab
thu
use
vlpexpress
plasmid
locat
formalinmodifi
epitop
recogn
mab
jev
vlp
ediii
amino
acid
substitut
jev
vlp
amino
acid
substitut
show
decreas
bind
mab
fig
amino
acid
locat
within
bc
loop
ediii
jev
amino
acid
locat
within
fg
loop
ediii
jev
three
amino
acid
like
candid
undergo
modif
formalin
inactiv
fig
bc
loop
ediii
contain
critic
residu
recogn
neutral
mab
jev
west
nile
viru
fg
loop
ediii
involv
host
tropism
therefor
analyz
neutral
abil
assay
fig
found
potenc
mab
mab
neutral
inhibit
flavivir
infect
postattach
step
thu
use
mab
determin
mechan
viral
neutral
mab
use
bind
jev
infect
vero
cell
order
carri
preattach
assay
altern
mab
ad
jevbound
cell
order
carri
postattach
assay
neutral
pattern
mab
similar
regardless
whether
either
mab
ad
viral
attach
fig
indic
mab
seem
inhibit
jev
postattach
step
evalu
influenc
epitop
ediii
immunogen
formalintr
jev
antigen
investig
igg
antibodi
respons
properti
antibodi
ediii
vaccin
mice
femal
balbc
mice
vaccin
ucvnakayama
fivnakayama
ficv
postvaccin
serum
sampl
analyz
iggcaptur
elisa
use
wildtyp
ediii
edii
vlp
edii
vlp
elimin
immunodomin
bcell
epitop
conserv
flavivirus
well
induc
crossreact
nonneutr
andor
lowneutr
antibodi
total
jevspecif
igg
elicit
three
immunogen
similar
p
averag
titer
endpoint
ucvnakayama
fivnakayama
ficvimmun
mice
respect
fig
panel
determin
antibodi
respons
recogn
edii
epitop
ediii
epitop
calcul
decreas
reactiv
titer
edii
ediii
vlp
characterist
untreat
control
nakayama
viru
ucvnakayama
formalininactiv
nakayama
viru
fivnakayama
day
antigen
reactiv
ucvand
fivnakayama
monitor
agelisa
use
mhiaf
data
od
two
duplic
b
infecti
virus
determin
plaqu
assay
formalin
treatment
c
mab
bind
activ
ucvnakayama
fivnakayama
evalu
agelisa
bind
activ
adjust
antigen
concentr
accord
od
mhiaf
compar
day
data
two
duplic
signific
differ
indic
asterisk
p
compar
wildtyp
vlp
titer
antibodi
recogn
edii
epitop
similar
p
serum
mice
vaccin
ucvnakayama
rang
fivnakayama
rang
ficv
rang
fig
panel
b
contrast
titer
ediii
epitopespecif
antibodi
significantli
lower
p
serum
mice
vaccin
fivnakayama
fiv
ucv
jev
detect
mab
c
quantif
mab
bind
activ
e
ucv
jev
valu
ucv
jev
shown
fiv
jev
valu
data
two
duplic
signific
differ
indic
asterisk
p
fig
panel
c
base
suspect
ficvimmun
children
might
produc
similarli
lower
proport
ediii
epitopespecif
antibodi
twelv
ficvimmun
children
serum
sampl
found
show
lower
level
ediii
epitopespecif
igg
antibodi
name
tabl
result
close
resembl
antibodi
reaction
elicit
fivnakayamaimmun
ficvimmun
mice
confirm
result
obtain
epitopespecif
igg
elisa
fivnakayama
ficv
immun
mous
serum
sampl
examin
western
blot
analysi
use
concentr
wt
edii
vlp
ediii
vlp
fig
result
quantifi
standard
protein
concentr
fig
prm
protein
jev
vlp
includ
wt
antigen
edii
antigen
ediii
antigen
equal
recogn
antijev
mhiaf
furthermor
edii
vlp
ediii
vlp
could
recogn
show
significantli
decreas
recognit
mab
name
reactiv
respect
serum
collect
mice
vaccin
ucvnakayama
less
abl
bind
ediii
vlp
fivnakayama
ficv
respect
true
edii
vlp
respect
fig
result
epitopespecif
igg
elisa
western
blot
analysi
consist
indic
stronger
immunogen
ediii
epitop
ucvnakayama
fivnakayama
ficv
therefor
formalininactiv
nakayama
viru
vaccin
immun
mice
abl
affect
induct
antibodi
recogn
ediii
abl
affect
induct
antibodi
recogn
edii
epitop
protect
efficaci
vaccin
jev
infect
posit
associ
presenc
neutral
antibodi
mice
base
evalu
correl
preadsorpt
neutral
antibodi
titer
mous
serum
immun
ucvnakayama
fivnakayama
ficv
similar
titer
respect
fig
measur
postadsorpt
titer
fig
determin
contribut
ediii
antibodi
viral
neutral
activ
neutral
antibodi
titer
lower
serum
postadsorb
wt
jev
vlpexpress
cell
serum
postadsorb
normal
cell
use
serum
sampl
elicit
three
vaccin
fig
howev
postadsorpt
serum
specimen
use
jev
ediii
vlpexpress
cell
show
signific
reduct
neutral
antibodi
titer
activ
serum
either
fivnakayamaimmun
mice
ficvimmun
mice
use
serum
ucvnakayamaimmun
mice
use
differ
neutral
activ
serum
sampl
adsorpt
cell
express
wt
vlp
ediii
vlp
may
due
contribut
made
ediii
antibodi
result
fit
use
nonlinear
regress
analysi
fig
show
contribut
ediii
antibodi
neutral
antibodi
activ
proport
higher
rang
use
serum
ucvnakayamaimmun
mice
serum
fivnakayamaimmun
mice
rang
ficvimmun
mous
serum
rang
use
thu
formalin
modif
ediii
epitop
would
seem
affect
product
neutral
antibodi
search
altern
method
use
product
inactiv
jev
vaccin
previou
report
suggest
jev
inactiv
formalin
day
might
immunogen
inactiv
day
therefor
ask
inactiv
temperatur
vs
inactiv
durat
day
vs
day
respect
abl
influenc
modif
measur
mab
bind
activ
je
nakayama
virus
treat
formalin
day
fig
mab
bind
activ
fivnakayama
lower
result
respect
thu
epitop
modif
present
fivjev
treat
either
day
remain
mab
bind
activ
day
remain
mab
bind
activ
fig
uv
also
use
inactiv
virus
past
uvinactiv
virus
abl
induc
protect
humor
immun
surprisingli
uvinactiv
nakayama
viru
weakli
bound
antijev
mhiaf
mab
assess
western
blot
analysi
indic
antigen
structur
nakayama
viru
might
sever
alter
uv
irradi
fig
hydrogen
peroxid
h
use
biocid
known
interact
amino
sulfhydryl
group
antigen
amanna
et
al
recent
report
h
inactiv
virus
still
abl
induc
protect
cellular
humor
immun
therefor
follow
protocol
inactiv
nakayama
viru
h
hr
twohour
h
treatment
reduc
viral
infect
least
detect
limit
fig
agcaptur
elisa
reveal
bind
activ
crossreact
mab
ucvnakayama
h
treat
nakayama
viru
treatment
suggest
antigen
structur
nakayama
viru
remain
intact
h
inactiv
fig
sever
countri
includ
japan
south
korea
taiwan
success
reduc
number
je
clinic
case
use
inactiv
jev
vaccin
effect
safe
altern
vaccin
still
need
factor
affect
effect
safeti
jev
vaccin
viru
strain
method
viral
cultiv
vaccin
puriti
vaccin
formul
howev
effect
formalin
inactiv
qualiti
vaccin
never
studi
import
formalininduc
hypersensit
found
associ
risk
enhanc
diseas
subsequ
infect
respiratori
syncyti
viru
rsv
formalin
inactiv
alter
antigen
polioviru
antigen
character
formalininactiv
polioviru
vaccin
use
panel
mab
reveal
modif
antigen
timedepend
use
previous
collect
panel
antiflaviviru
mab
establish
agelisa
found
mab
bind
domain
timeand
temperaturedepend
alter
formalin
inactiv
observ
suggest
might
valuabl
evalu
effect
residu
formalin
formul
bulk
vaccin
shelf
life
futur
importantli
regardless
jev
strain
use
formalin
treatment
alter
epitop
test
je
virus
contrast
epitop
recogn
mab
fivnakayama
temporarili
modifi
specimen
collect
earli
time
point
modif
two
epitop
nakayama
strainspecif
revers
sinc
phenomenon
observ
earli
time
point
specimen
formalintr
nakayama
alon
among
antiflaviviru
antibodi
virusspecif
noncrossreact
ediiirecogn
antibodi
strongli
neutral
activ
crossreact
ediior
edirecogn
antibodi
weak
neutral
activ
mab
jevderiv
jevserocomplex
crossreact
antibodi
show
weakli
neutral
activ
postattach
step
vitro
howev
antibodi
compris
larg
portion
antibodi
respons
wnv
infect
weak
neutral
activ
vitro
still
provid
therapeut
protect
vivo
via
immun
complement
system
amino
acid
residu
edii
ediii
e
protein
import
bind
jev
serocomplex
crossreact
mab
determin
bind
mab
jev
vlp
amino
acid
posit
use
ediii
vlp
analyz
epitopespecif
antibodi
respons
vlp
show
reduc
secret
interestingli
epitop
overlap
jevspecif
highli
neutral
mab
epitop
result
provid
addit
support
eprotein
epitop
within
flavivirus
overlap
formalin
known
mainli
react
amino
thiol
group
amino
acid
form
methylol
group
follow
format
schiffbas
adduct
reaction
revers
schiffbas
adduct
crosslink
function
group
variou
amino
acid
arginin
tyrosin
tryptophan
histidin
glutamin
lysin
cystein
form
nonrevers
methylen
bridg
thu
epitop
mab
name
glycin
serin
serin
aspart
acid
like
directli
modifi
formalin
possibl
influenc
nearbi
amino
acid
includ
crosslink
might
directli
indirectli
affect
conform
structur
epitop
formalin
treatment
alter
epitop
recogn
mab
might
sensit
formalingener
modif
nonoverlap
residu
essenti
recognit
current
still
know
residu
specif
react
formalin
structur
differ
amino
acid
variat
flaviviru
immunogen
whether
virion
matur
immatur
vlp
ediii
alon
may
also
affect
immunogen
antibodi
profil
neutral
potenc
elicit
exampl
ediiireact
antibodi
show
high
neutral
potenc
recombin
ediii
immunogen
induc
low
avid
low
titer
neutral
antibodi
viru
studi
found
formalin
inactiv
alter
structur
jev
e
protein
thu
affect
profil
induc
antibodi
studi
epitop
epitop
affect
formalin
inactiv
howev
whether
epitop
e
structur
alter
affect
profil
antibodi
elicit
formalininactiv
vaccinesvirus
unknown
epitop
ediii
directli
reactiv
formalin
formalinmodifi
ediii
region
found
less
immunogen
less
contribut
neutral
activ
despit
nonsignific
differ
neutral
antibodi
titer
among
ucvnakayamaimmun
mice
fivnakayamaimmun
mice
weakneutr
nonneutr
epitop
locat
fusion
peptid
introduct
mutat
fusion
peptid
vlp
disrupt
bind
activ
antifus
loop
mab
fusion
peptid
mutant
reduc
immunogen
fusion
peptid
retain
abil
evok
neutral
antibodi
thu
formalinmodifi
region
affect
profil
vaccineinduc
antibodi
alter
distribut
neutral
antibodi
determin
effect
formalin
inactiv
tcell
respons
need
address
neg
effect
formalininactiv
influenzaviru
tcell
respons
document
tcell
immun
play
role
vaccin
protect
jev
infect
use
epitop
scaffold
deglycosyl
success
expos
immunorepress
cryptic
epitop
enhanc
immunogen
hiv
redirect
antibodi
respons
simian
immunodefici
viru
found
titer
ediii
antibodi
higher
among
ucvnakayamathan
fivnakayamaor
ficvimmun
mice
use
edii
antibodi
gave
similar
result
previous
found
edii
ediii
form
overlap
epitop
flaviviru
group
crossreact
mab
thu
edii
region
may
less
like
cooper
ediii
region
induc
antibodi
respons
immunogen
modifi
formalin
formalininactiv
lactat
dehydrogenaseelev
viruselicit
antibodi
differ
antibodi
natur
infect
formalininactiv
influenza
viru
could
induc
tcell
respons
less
protect
mice
homolog
heterolog
influenza
viru
challeng
compar
viru
howev
anoth
studi
indic
use
low
formalin
concentr
short
inactiv
period
high
incub
temperatur
improv
immunogen
formalininactiv
jev
vaccin
elicit
high
titer
neutral
antibodi
mice
show
bind
activ
mab
reduc
viru
inactiv
treatment
durat
surprisingli
uvinactiv
nakayama
viru
fail
recogn
mhiaf
adjust
condit
uv
irradi
may
maintain
antigen
structur
jev
uv
light
inactiv
viru
crosslink
viral
nucleic
acid
viral
protein
crosslink
oxid
amino
acid
residu
may
increas
suscept
proteas
cleavag
degrad
aromat
side
chain
amino
acid
disulfid
bond
form
cystein
protein
indic
uv
treatment
loss
viral
antigen
also
observ
uvinactiv
viru
includ
polioviru
show
antigen
morpholog
chang
influenza
viru
exhibit
low
hemagglutin
activ
murray
valley
enceph
viru
belong
jev
serocomplex
inactiv
uv
show
lower
immunogen
compar
noninfecti
vlp
uvinduc
antigen
chang
nt
describ
conclus
formalin
uv
inactiv
alter
antigen
structur
e
protein
jev
reduc
immunogen
associ
vaccin
h
inactiv
seem
better
altern
jev
vaccin
product
maintain
antigen
structur
e
protein
measur
panel
mab
studi
focu
identifi
optim
inactiv
procedur
test
immunogen
h
inactiv
jev
vaccin
final
prevent
unexpect
modif
variou
epitop
jev
vaccin
inactiv
noninfecti
jev
vlp
dna
vaccin
develop
formalin
inactiv
introduc
antigen
modif
affect
ediii
jev
thu
distort
profil
vaccineinduc
neutral
antibodi
antigenicst
inactiv
method
need
develop
betterinactiv
jev
vaccin
tabl
epitopespecif
antibodi
respons
serum
sampl
collect
ficvimmun
children
pdf
